Aptevo Therapeutics (APVO) Retained Earnings (2016 - 2025)
Aptevo Therapeutics (APVO) has disclosed Retained Earnings for 11 consecutive years, with -$269.2 million as the latest value for Q3 2025.
- Quarterly Retained Earnings fell 11.59% to -$269.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$269.2 million through Sep 2025, down 11.59% year-over-year, with the annual reading at -$247.6 million for FY2024, 10.8% down from the prior year.
- Retained Earnings hit -$269.2 million in Q3 2025 for Aptevo Therapeutics, down from -$260.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$192.9 million in Q1 2021 to a low of -$269.2 million in Q3 2025.
- Historically, Retained Earnings has averaged -$222.8 million across 5 years, with a median of -$217.5 million in 2023.
- Biggest five-year swings in Retained Earnings: fell 16.92% in 2021 and later increased 8.34% in 2023.
- Year by year, Retained Earnings stood at -$214.1 million in 2021, then grew by 3.75% to -$206.0 million in 2022, then decreased by 8.45% to -$223.4 million in 2023, then decreased by 10.8% to -$247.6 million in 2024, then fell by 8.74% to -$269.2 million in 2025.
- Business Quant data shows Retained Earnings for APVO at -$269.2 million in Q3 2025, -$260.2 million in Q2 2025, and -$254.0 million in Q1 2025.